Sponsored by MaxCyte
MaxCyte’s delivery platform is a universal, high-performance transfection technology that significantly reduces risk and shortens biotherapeutic development timelines by enabling researchers to
Perform early-stage development in the biomanufacturing host cell to ensure identification of high quality, biorelevant candidates
Expand the use of transient transfection for faster candidate identification
Make rapid and more informed go/no-go decisions through in-depth candidate characterization using transiently produced materials, thus reducing investments associated with stable cell line generation
Expedite the transition to biomanufacturing through improved stable cell line generation.
Gram-Scale Production of Quality Antibodies: MaxCyte’s Flow Electroporation™ technology is a fully scalable, high efficiency means of transiently producing milli- to multigram quantities of antibodies in the host cell line-of-choice without the need for specialized reagents, vectors, or engineered cell lines. CHO cell transfection efficiencies and cell viabilities of >95% enable rapid, high-titer expression of antibodies (Figure 1) and antibody-like molecules. The high level of antibody quality in combination with the seamless scalability and regulatory pathway of MaxCyte’s delivery platform uniquely fulfill the needs of R&D activities through CGMP pilots and toxicology studies.
You May Also Like
